Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opti-HER2: De-escalated THP vs Standard TCHP in Early HER2+ Breast Cancer
NCT07421141Phase 2Active, not recruiting
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection in HER2-positive breast cancer. Started Sep 2023; status: active, not recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07421141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421141.